文献速递淋巴瘤

利用成纤维细胞生长因子受体-1的脆弱性治疗性限制套细胞淋巴瘤中MYC-EZH2-CDKN1C轴驱动的增殖

Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.
PubMed 文献 · Leukemia · 2023-08-19

套细胞淋巴瘤(MCL)中位生存期4年,治疗选择有限。整合转录组分析发现FGFR1高表达与MCL患者总生存期缩短相关,功能研究揭示MYC-EZH2-CDKN1C轴驱动增殖。FGFR选择性小分子厄达替尼在体外诱导细胞周期阻滞和细胞死亡,在体内抑制肿瘤进展并改善总生存,临床前模型证实FGFR1为可行治疗靶点。

要点

  • MCL患者中FGFR1高表达与总生存期缩短相关。
  • FGFR1通过MYC-EZH2-CDKN1C轴驱动MCL增殖。
  • 厄达替尼在体外诱导细胞周期阻滞和细胞死亡,在体内抑制肿瘤进展并改善总生存。

核心结论

  • FGFR1是MCL可行的治疗靶点,厄达替尼在临床前模型中显示治疗潜力。

研究设计与样本

  • 研究对MCL患者样本进行整合转录组分析,并开展功能研究及多种体内模型的广泛临床前评估。

主要发现

  • MCL患者样本分析显示FGFR1高表达与患者队列总生存期缩短相关。
  • 功能研究识别出MYC-EZH2-CDKN1C轴驱动的MCL增殖。
  • 厄达替尼在体外诱导细胞周期阻滞和细胞死亡,在体内抑制肿瘤进展并改善总生存。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) is a lethal hematological malignancy with a median survival of 4 years. Its lethality is mainly attributed to a limited understanding of clinical tumor progression and resistance to current therapeutic regimes. Intrinsic, prolonged drug treatment and tumor-microenvironment (TME) facilitated factors impart pro-tumorigenic and drug-insensitivity properties to MCL cells. Hence, elucidating neoteric pharmacotherapeutic molecular targets involved in MCL progression utilizing a global "unified" analysis for improved disease prevention is an earnest need. Using integrated transcriptomic analyses in MCL patients, we identified a Fibroblast Growth Factor Receptor-1 (FGFR1), and analyses of MCL patient samples showed that high FGFR1 expression was associated with shorter overall survival in MCL patient cohorts. Functional studies using pharmacological intervention and loss of function identify a novel MYC-EZH2-CDKN1C axis-driven proliferation in MCL. Further, pharmacological targeting with erdafitinib, a selective small molecule targeting FGFRs, induced cell-cycle arrest and cell death in-vitro, inhibited tumor progression, and improved overall survival in-vivo. We performed extensive pre-clinical assessments in multiple in-vivo model systems to confirm the therapeutic potential of erdafitinib in MCL and demonstrated FGFR1 as a viable therapeutic target in MCL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Sircar A, Singh S, Xu-Monette ZY, et al. Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma. Leukemia. 2023. PMID: 37598282. doi:10.1038/s41375-023-02006-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。